Lymphomas are an attractive target for the use of ADCs, bearing many surface markers that are largely restricted to the mature B and/or T cell lineage, as shown by the efficacy of anti-CD20 monoclonal Abs or CAR T cell therapy targeting CD19. The gene discussed is CD19; the disease is lymphoma.